Item 8.01 Other Events.

On January 24, 2023, Baudax Bio, Inc. (the "Company") issued a press release announcing the positive outcome of interim analysis of Phase II randomized trial for BX1000. A copy of this press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:



Exhibit
  No.       Document

99.1          Press release of Baudax Bio, Inc., dated January 24, 2023.

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses